The uniportal VATS in the treatment of stage II pleural empyema: a safe and effective approach for adults and elderly patients—a single-center experience and literature review

Claudio Luciani1, Andrea Scacchi2†, Roberto Vaschetti2†, Giancarlo Di Marzo1, Ilaria Fatica2, Micaela Cappuccio2, Germano Guerra2, Graziano Ceccarelli3, Pasquale Avella2*† and Aldo Rocca2†

Abstract

Background: Pleural empyema (PE) is a frequent disease, associated with a high morbidity and mortality. Surgical approach is the standard of care for most patients with II-III stage PE. In the last years, the minimally invasive surgical revolution involved also thoracic surgery allowing the same outcomes in terms of safety and effectiveness combined to better pain management and early discharge. The aim of this study is to demonstrate through our experience on uniportal-video-assisted thoracoscopy (u-VATS) the effectiveness and safety of its approach in treatment of stage II PE. As secondary endpoint, we will evaluate the different pattern of indication of u-VATS in adult and elderly patients with literature review.

Methods: We retrospectively reviewed our prospectively collected database of u-VATS procedures from November 2018 to February 2022, in our regional referral center for Thoracic Surgery of Regione Molise General Surgery Unit of “A. Cardarelli” Hospital, in Campobasso, Molise, Italy.

Results: A total of 29 patients underwent u-VATS for II stage PE. Fifteen (51.72%) patients were younger than 70 years old, identified as “adults,” 14 (48.28%) patients were older than 70 years old, identified as “elderly.” No mortality was found. Mean operative time was 104.68 ± 39.01 min in the total population. The elderly group showed a longer operative time (115 ± 53.15 min) (p = 0.369). Chest tube was removed earlier in adults than in elderly group (5.56 ± 2.06 vs. 10.14 ± 5.58 p = 0.038). The Length of Stay (LOS) was shorter in the adults group (6.44 ± 2.35 vs. 12.29 ± 6.96 p = 0.033). Patients evaluated through Instrumental Activities of Daily Living (IADL) scale returned to normal activities of daily living after surgery.

Conclusion: In addition, the u-VATS approach seems to be safe and effective ensuring a risk reduction of progression to stage III PE with a lower recurrence risk and septic complications also in elderly patients. Further comparative multicenter analysis are advocated to set the role of u-VATS approach in the treatment of PE in adults and elderly patients.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Pleural empyema (PE) is a clinical condition defined as the presence of purulent fluid in the pleural cavity and characterized by high morbidity and an estimated mortality rate of 15% [1].

The surgical approach to PE is determined by its evolutive stage and it is the standard of care in the 36–65% of patients [2].

Empyema thoracis is classified into three stages, according to the European Association for Cardio-Thoracic Surgery (EACTS) guidelines [3]: the exudative phase (stage I) is characterized by a collection of flowing fluid into the pleural cavity in the absence of positive culture. The fibrinopurulent phase (stage II), a turbid and frankly infected fluid, with loculations and fibrinous septa formation. Lastly, the chronic organizing phase (stage III), with scar adhesions and a progressive constriction, process that leads to a “trapped lung.”

EACTS guidelines recommend parenteral antibiotics combined to image-guided pleural drain placement for the first stage of PE, instead, surgery should be considered the first-line approach in the management of the last stages when single lung ventilation is tolerated either in minimally invasive approach, either through open surgery [1, 3]. In cases where such surgical intervention or ventilation cannot be tolerable for the patient, intrapleural fibrinolysis may be an alternative approach [3].

The advent of minimally invasive surgery (MIS) approaches and technological improvements have led to significant amelioration in peri-operative patients’ outcomes also in complex surgical fields [4–8]. Following the general surgery experience in MIS approaches also thoracic surgery have demonstrated the safety and efficacy of surgical approach through minimally invasive video-assisted thoracoscopy (VATS).

Nowadays, multiportal VATS (m-VATS), and its evolution uniportal-VATS (u-VATS), gained a key role in diagnosis and treatment of pulmonary and non-pulmonary morbidities [9, 10].

Furthermore, also the u-VATS approach to pulmonary cancers and pleural disease seemed to be related to enough safe and effective allowing better postoperative outcomes when compared to standard thoracotomy [2, 11, 12].

Although an increasing number of centers have reported VATS approach to treat intermediate stages of PE a lack of published data still persists on the use of u-VATS.

Therefore, our aim is to demonstrate through our experience on u-VATS the effectiveness and safety of its approach in treatment of stage II PE. As secondary endpoint we will evaluate the different pattern of indication of this both in adult and elderly patients with an extensive literature review.

Methods

We retrospectively reviewed our prospectively collected database of u-VATS procedures from the institution of a dedicated thoracic surgical team on November 2018 to February 2022, according to Strengthening the Reporting of Observational studies in Epidemiology (STROBE) [13], in our regional referral center for Thoracic Surgery of Regione Molise General Surgery Unit of “A. Cardarelli” Hospital, in Campobasso, Molise, Italy (Fig. 1).

Grade of eligibility was defined by the presence of a stage II PE fitting for surgery, according to the American Association of Thoracic Surgery (AATS) classification, evaluated through biochemical investigations, such as the alterations of flogosis indices, and instrumental investigations, like ultrasound (US), chest-XR and computed tomography (CT) scan [1] (Fig. 2).

Surgical exclusion criteria were: lack of patient compliance, the presence of lung cancer, chest trauma, non-pulmonary surgery and stage III PE.

Anesthesiological exclusion criteria were: lack of patient compliance, right ventricular dysfunction, hemodynamic instability, severe chronic obstructive pulmonary disease (COPD), severe pulmonary hypertension and other comorbidities which make it impossible to perform a single lung ventilation (Fig. 1).

Study exclusion criteria were: patients managed by general surgeons not involved in thoracic team before its institution, any data not prospectively collected.

A team composed of thoracic surgeons, anesthesiologist, infectious disease specialist and internist/pulmonologist discussed all cases, placing surgical indication, according to the EACTS guidelines [3]. American Society of Anesthesiologist (ASA) score was used to evaluate intraoperative risk [14].

Before surgery, all patients performed routine blood samples, electrocardiogram (ECG), and start a broad-spectrum antibiotic therapy including metronidazole with parental second or third cephalosporin generation (more frequent ceftriaxone) or parental aminopenicillin

Keywords: Thoracic surgery, Pleural empyema, Minimally invasive surgery, Frailty, Uniportal video-assisted thoracoscopy, Decortication
with β-lactamase inhibitor (more frequent ampicillin/sulbactam) according to AATS guideline [1].

Due to the high incidence of the severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) over the years of this study, all patients performed a rhino-pharyngeal molecular swab before the admission in the general surgery ward.

After surgery, all patients performed a chest-XR or CT scan to visualize lung re-expansion.

To achieve a rapid recovery of patient’s conditions, the enhanced recovery after surgery (ERAS) program was used [15].

Postoperative complications were assessed according to the Clavien–Dindo classification [16].
Treatment of postoperative anemia, a frequent complication during thoracic surgery, was performed according to our general surgery unit protocol (Additional file 1).

Postoperative pain was evaluated, every morning, through Visual Analogue Scale (VAS) [17].

Follow-up was planned at 1 week after discharge, using lung US, and 30 days, using chest-XR, after discharge. In either adult and elderly patients, Instrumental Activities of Daily Living (IADL) scale was administered in order to understand the return to normal activities of daily living [18].

All individuals included in this study signed an informed consent for the scientific anonymous use of clinical data. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of Molise (protocol number 10/21, approved date: May 12, 2021).

Technical Notes

u-VATS Technique

All procedures were performed under general anesthesia and single lung ventilation, using a double-lumen endotracheal tube. The patient was put in lateral decubitus position with the arms flexed toward the head. To allow a better intercostal space extension, the operating table was flexed into a wedge position with the patient’s head and lower limbs slightly inclined.

After careful skin disinfection with iodopovidone 10%, an ultrasound-guided block of the serratus anterior plane (SAP block with ropivacaine 0.25%, 30 ml) was performed to achieve a better postoperative pain management (Fig. 3).

The operating surgeon and the assistant stand in front of the patient and the video-monitor.

At the level of the fifth intercostal space, in the correspondence of the mid axillary line, a single incision of 2–3 cm, preserving the muscular structure, was made. Subsequently, to ensure incision enlargement and protection of the structure, a wound protector was inserted. At
this point, a 5 mm or 10 mm 30° thoracoscope and endoscopic instruments were introduced (Fig. 4).

To achieve a complete lung re-expansion, the operation continued with debridement and removal of all adhesions, septa, and inflammatory effusion from both the visceral and the parietal pleura (Fig. 5).

In case of difficulty in operating management through thoracoscopy, an anterolateral thoracotomy was performed.

Multiple washings with warm physiological solution (NaCl 0.9% solution) were performed to eliminate the residual effusion and organized pus from the visceral pleura. The operation proceeded with decortication with an electrocautery device.

Parenchymal re-expansion was evaluated with lung inflation, and at the same time an accurate aerostasis’ control was carried out.

At the end of surgery, one or two chest tube drainages (28–32 French) were placed.

The timing of chest tube removal was inspired by postsurgical factors (no air leak, drained fluid of clear appearance, whose quantity in 24 h was less than 450 ml) [15], clinical aspects (quantitative decrease of inflammatory indices, fever) and radiological evidence of complete lung re-expansion.

Postoperatively, patients continued with the antibiotic regimen instituted preoperatively and analgesics, such as paracetamol (1000 mg/100 ml) or ketorolac (30 mg/ml), as needed for pain control. Gradually then, patients were referred to respiratory physiotherapy.

Statistical analysis
Statistical analysis was designed to better define the safety and effectiveness of u-VATS in both adults (age < 70 years) and elderly (age ≥ 70 years).

A two-tailed p value < 0.05 was accepted as statistically significant.

First, we applied the Shapiro–Wilk test, to test the normal distribution of quantitative elements. Later, independent samples, whose distribution was normal, were tested using the unpaired t-test. The Mann–Whitney test was used in case of non-normal distributions of values.

Quantitative data were expressed like mean ± standard deviation (SD). We used the random-effects model to calculate summary 95% confidence interval (C.I.).

Chi-square test (\( \chi^2 \)) or Fisher’s exact test was used for qualitative data.

Data analysis was carried out with IBM Statistical Package for the Social Sciences (IBM SPSS®).

Results
Twenty-nine patients, 21 (72.41%) male and 8 (27.59%) female, underwent u-VATS surgery from November 2018 to February 2022. Fifteen (51.72%) patients were younger than 70 years old defined as “adults,” and 14 (48.28%) were elderly than 70 years defined as “elderly.” Total population mean age was 67.13 ± 9.66 years (95% C.I. 63.34–70.91). In the adults group, the mean age was 59.84 ± 5.34 (95% C.I. 56.88–62.79); meanwhile, in the elderly group the mean age was 76.51 ± 5.25 (95% C.I. 73.47–79.54). A statistically significant difference was found between the average ages of the two groups (\( p < 0.001 \)).

Hypertension (68.96%) was the most frequent comorbidity, both in adults (66.67%) and in elderly (71.42%). According to the ASA score, 12 (41.38%) patients were ASA 2, 11 (37.93%) were ASA 3, and 6 (20.69%) were ASA 4 (\( p = 0.017 \)). ASA score according to age is reported in Table 1.

All PE (100%) were stage II affecting left hemithorax in the 68.97%.

The main patient’s demographic and clinical characteristics are shown in Table 1.

Five (17.24%) patients had parapneumonic empyema related to an ongoing acute pulmonary infectious process, 3 (20.00%) of these patients were adults.

Fever, at the admission, was the main symptom in 44.83% of the series, as shown in Table 2.

The difference in the presence of fever between adults and elderly has been found as statistically significant (\( p = 0.005 \)). The presence of a cough as a clinical presentation was observed in 4 (100%) patients, all included in the elderly group (\( p = 0.042 \)).

All patients (100%) were treated with broad-spectrum antibiotic therapy; 5 (33.33%) adults patients were also administered a corticosteroid therapy.

Mean operative time was 104.68 ± 39.01 (95% C.I. 89.84–119.52) min in the total population. The elderly group showed a longer operative time (115 ± 53.15 min, 95% C.I. 84.31–145.69) without any statistical significance (\( p = 0.369 \) (Table 2).

Only in 1 (3.45%) adult case conversion was necessary.

Table 2 illustrates the main preoperative, intraoperative, and postoperative characteristics. All patients (100%) achieved optimal lung re-expansion, and no air leaks were reported in any patient, at radiographic control.

No intraoperative or postoperative hemotransfusions were required.

No intraoperative mortality was reported.

No intensive care unit (ICU) admission was necessary (Table 2).
Postoperative complications according to Clavien–Dindo classification are depicted in Table 2.

Minor complications occurred in 18 (62.07%) patients, atelectasis was the most reported minor complication, 7 (46.67%) cases in the adults group, and 8 (57.14%) in the elderly group ($p = 0.573$) (Table 3).

No surgical wound infections or local paresthesia occurred, as shown in Table 3.

Mean pain duration after surgery was $2.80 \pm 0.83$ days (95% C.I. 2.49–3.11). Seventeen (58.62%) patients, 7 (46.67%) in the adults group, and 10 (71.43%) in the elderly group required additional postoperative antalgic coverage.

Chest tube was removed after $7.56 \pm 4.50$ days (95% C.I. 5.85–9.27); in the adults group, the mean chest tube removal was $5.56 \pm 2.06$ days (95% C.I. 4.42–6.70); for the elderly group, it was $10.14 \pm 5.58$ days (95% C.I. 6.92–13.36). After statistical analysis, we found a statistically significant difference ($p = 0.038$).

The mean postoperative length of stay (LOS) in the total population was $9.00 \pm 5.59$ days (95% C.I. 6.87–11.12), greater in the elderly group (12.29 ± 9.70, 95% C.I. 8.27–16.31), and shorter in the adults group (6.44 ± 2.35, 95% C.I. 5.14–7.74). A statistically significant difference was found ($p = 0.033$) (Table 2).

After over-30-day of follow-up, 26 (89.65%) patients returned to normal activities of daily living, with a mean IADL score equal to 8, without any recurrence of disease and without any significant difference between group. Three (10.35%) patients, all elderly, had a mean IADL score equal to 6.

Discussion

Our study demonstrates the safety of minimally invasive u-VATS procedure in the treatment of stage II PE. The postoperative results achieved by the thoracoscopic approach were remarkable, fully satisfying the two main goals of PE treatment:

**Table 1** Baseline characteristic of patients

| Variables                          | N. (%) and/or Mean ± SD | Total population (n. = 29) | Adults (age < 70; n. = 15) | Elderly (age ≥ 70; n. = 14) | $p$ value |
|------------------------------------|-------------------------|---------------------------|-----------------------------|----------------------------|-----------|
| Age (years)                        | 67.13 ± 9.96            | 59.84 ± 5.34              | 76.51 ± 5.25                | $< 0.001$                  |           |
| Gender                             |                         |                           |                             |                            | 0.035     |
| Male                               | 21 (72.41)              | 8 (53.33)                 | 13 (92.86)                  |                           |           |
| Female                             | 8 (27.59)               | 7 (46.67)                 | 1 (7.14)                    |                           |           |
| ASA                                |                         |                           |                             |                            | 0.017     |
| II                                 | 12 (41.38)              | 8 (53.33)                 | 4 (28.57)                   |                           |           |
| III                                | 11 (37.93)              | 7 (46.67)                 | 4 (28.57)                   |                           |           |
| IV                                 | 6 (20.69)               | 0 (0)                     | 6 (42.86)                   |                           |           |
| Smoker                             | 13 (44.83)              | 7 (46.67)                 | 6 (42.86)                   |                           | 0.873     |
| Comorbidities                      |                         |                           |                             |                            |           |
| Hypertension                       | 20 (68.96)              | 10 (66.67)                | 10 (71.42)                  |                           |           |
| COPD                               | 10 (34.48)              | 2 (13.33)                 | 8 (57.14)                   |                           | 0.021     |
| Heart disease                      | 10 (34.48)              | 2 (13.33)                 | 8 (57.14)                   |                           | 0.021     |
| Diabetes                           | 4 (13.79)               | 2 (13.33)                 | 2 (14.29)                   |                           |           |
| SARS-CoV-2 swab positivity         | 0 (0)                   | 0 (0)                     | 0 (0)                       |                           |           |
| Pleural empyema stage              |                         |                           |                             |                            |           |
| I                                  | 0 (0)                   | 0 (0)                     | 0 (0)                       |                           |           |
| II                                 | 29 (100)                | 15 (100)                  | 14 (100)                    |                           |           |
| III                                | 0 (0)                   | 0 (0)                     | 0 (0)                       |                           |           |
| Affected lung                      |                         |                           |                             |                            |           |
| Left                               | 20 (68.97)              | 12 (80.00)                | 8 (57.14)                   |                           |           |
| Right                              | 9 (31.03)               | 3 (20.00)                 | 6 (42.86)                   |                           |           |

SD, standard deviation; ASA, American Society of Anaesthesiologists Physical Score; COPD, chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
• a meticulous debridement of the pleural cavity and complete decortication of the visceral and parietal pleura in all 29 patients;
• adequate lung re-expansion in 100% of the series.

Furthermore, we report the first experience on u-VATS approach to stage II PE in elderly population older than 70 years. Our findings demonstrated the same outcomes in terms of efficacy and safety than in adult, showing a longer chest tube stay and hospital stay that we will discuss below.

Until a few years ago, the standard of care for stages II and III PE was represented by thoracotomy, but nowadays MIS gained even more diffusion as reported by several studies which compared thoracotomy and VATS

### Table 2 Pre-, intra- and postoperative course and characteristics

| Variables                                | Total population (n. = 29) | Adults (age < 70; n. = 15) | Elderly (age ≥ 70; n. = 14) | p value |
|------------------------------------------|----------------------------|-----------------------------|-----------------------------|---------|
| **Preoperative characteristic**         |                            |                             |                             |         |
| Preoperative pulmonary infection         | 5 (17.24)                  | 3 (20.00)                   | 2 (14.29)                   |         |
| **Clinical presentation**                |                            |                             |                             |         |
| Fever                                    | 13 (44.83)                 | 3 (20.00)                   | 10 (71.42)                  | 0.005   |
| Cough                                    | 4 (13.79)                  | 0 (0)                       | 4 (28.57)                   | 0.042   |
| Dyspnea                                  | 6 (20.69)                  | 2 (13.33)                   | 4 (28.57)                   | 0.390   |
| **Preoperative flogosis indices**        |                            |                             |                             |         |
| WBC count ($\times 10^3$/μL)            | 10.84 ± 4.33               | 11.54 ± 3.34                | 10.14 ± 5.31                | 0.565   |
| PCR (mg/L)                               | 142.26 ± 131.77            | 87.60 ± 128.70              | 210.60 ± 114.06             | 0.190   |
| PCT (ng/mL)                              | 2.16 ± 3.10                | 3.50 ± 4.66                 | 1.49 ± 2.64                 | 0.533   |
| **Preoperative treatment**               |                            |                             |                             |         |
| Antibiotic therapy                       | 29 (100)                   | 15 (100)                    | 14 (100)                    |         |
| Corticosteroids                          | 5 (17.24)                  | 5 (33.33)                   | 0 (0)                       |         |
| Preoperative chest tube                  | 9 (31.03)                  | 7 (46.67)                   | 2 (14.29)                   | 0.109   |
| Preoperative fibrinolytic therapy        | 0 (0)                      | 0 (0)                       | 0 (0)                       |         |
| Preoperative lung re-expansion           | 0 (0)                      | 0 (0)                       | 0 (0)                       |         |
| **Intraoperative course**                |                            |                             |                             |         |
| Conversion to thoracotomy                | 1 (3.45)                   | 1 (6.67)                    | 0 (0)                       |         |
| **Number of chest tube**                 |                            |                             |                             |         |
| 1                                        | 25 (86.20)                 | 13 (86.67)                  | 12 (85.71)                  |         |
| 2                                        | 4 (13.80)                  | 2 (13.33)                   | 2 (14.29)                   |         |
| Estimated blood loss (ml)                | 118 ± 73.5                 | 110 ± 63                    | 126 ± 84                    |         |
| Re-expansion of the lung                | 29 (100)                   | 15 (100)                    | 14 (100)                    |         |
| Operating time                           | 104.68 ± 39.01             | 96.67 ± 23.84               | 115 ± 53.15                 | 0.369   |
| **Postoperative course**                 |                            |                             |                             |         |
| Clavien–Dindo classification             |                            |                             |                             |         |
| I                                        | 18 (62.07)                 | 6 (40.00)                   | 12 (85.71)                  |         |
| II                                       | 0 (0)                      | 0 (0)                       | 0 (0)                       |         |
| III                                      | 0 (0)                      | 0 (0)                       | 0 (0)                       |         |
| IV                                       | 0 (0)                      | 0 (0)                       | 0 (0)                       |         |
| ICU admission                            | 0 (0)                      | 0 (0)                       | 0 (0)                       |         |
| Postoperative antibiotic therapy         | 29 (100)                   | 15 (100)                    | 14 (100)                    |         |
| Postoperative Hb value (g/dL)            | 8.80 ± 0.96                | 9.40 ± 0.87                 | 8.20 ± 1.06                 |         |
| LOS (days)                               | 9.00 ± 5.59                | 6.44 ± 2.35                 | 12.29 ± 6.96                | 0.033   |
| Mean pain duration (days)                | 2.80 ± 0.83                | 2.50 ± 0.70                 | 3.00 ± 1.00                 | 0.591   |
| Painkillers needed                       | 17 (58.62)                 | 7 (46.67)                   | 10 (71.43)                  | 0.167   |
| Chest tube removal (days)                | 7.56 ± 4.50                | 5.56 ± 2.06                 | 10.14 ± 5.58                | 0.038   |

SD, standard deviation; WBC, white blood cell; PCR, protein-C reactive; PCT, procalcitonin; ICU, intensive care unit; Hb, hemoglobin; LOS, length of stay
 approaches to treat stage II-III PE reporting equivalent results in terms of safety and efficacy [19–22].

Furthermore, VATS achieved the additional benefits of the minimally invasive approach, including reducing postoperative pain and days of chest tube stay with early discharge [19, 20, 22, 23].

Although it seemed to be clear that our approach allowed a safety management of stage II PE, we compared our peri-operative data with the most relevant experiences on m-VATS and open approaches in order to deeply understand benefits and drawbacks of uniportal approach as resumed in Tables 4 and 5.

Comparing our results with studies concerning patients undergoing VATS (either uniportal or multiporal approach) (Tables 4 and 5), it is possible to highlight that our outcomes do not differ from the standard of care, also showing better results in terms of 30-days mortality [24–26].

Concerning preoperative patients' characteristics, we report a mean age of 67.13 ± 9.96 years, that is 15 years average higher than the average age reported in PE case series [19, 21–33].

Obviously, also comorbidities prevalence, like hypertension, COPD, and cardiovascular diseases, are higher in our population due to older patients [34–36].

Literature data concerning conversion rate to thoracotomy are heterogeneous, ranging from 6% [20, 26, 31] up to 59% [30]. This discrepancy is related either to the progressive learning curve either to the stage of the disease treated.

According to Stefani et al. [31], the probability of thoracotomy raises according to the waiting time for surgery; this finding can be linked to the evolution of stage II to a

### Table 3 Minor complications presentation

| Variables | Total population (n. = 29) | Adults (age < 70; n. = 15) | Elderly (age ≥ 70; n. = 14) | p value |
|-----------|-----------------------------|-----------------------------|-----------------------------|---------|
| Atelectasis | 14 (48.27) | 7 (46.67) | 8 (57.14) | 0.573 |
| Anemia | 13 (44.83) | 3 (20.00) | 10 (71.42) | 0.005 |
| Air-leakage | 0 (0) | 0 (0) | 0 (0) | |
| Wound infection | 0 (0) | 0 (0) | 0 (0) | |
| Postoperative paresthesia | 0 (0) | 0 (0) | 0 (0) | |

SD, standard deviation

### Table 4 Literature review—preoperative characteristics

| Author, year | Total population | Age, mean ± SD or mean and (range) | Pleural empyema stage | Treatment | Chest tube | VATS | Open |
|--------------|------------------|-----------------------------------|----------------------|-----------|------------|-----|------|
| Landreneau et al. [23] | 76 | 47 [14–78] | II-III | 0 | 0 | 76 | 0 |
| Wait et al. [19] | 20 | VATS 42 ± 20/CT 43 ± 13 | II | 9 | 0 | 11 | 0 |
| Angelillo Mackinlav et al. (24) | 64 | VATS 48.9 ± 17.6/ Open 51.1 ± 17.8 | II | 0 | 0 | 31 | 33 |
| Cassina et al. [27] | 45 | 52 [13–86] | II | 0 | 0 | 45 | 0 |
| Roberts et al. [25] | 172 | 53.68 [13–86] | II-III | 0 | 0 | 66 | 106 |
| Kim et al. [28] | 70 | 40 ± 15 | II-III | 0 | 0 | 70 | 0 |
| Lardinois et al. [29] | 328 | 55 [3–92] | II | 0 | 0 | 178 | 150 |
| Solaini et al. [30] | 110 | 52 [7–88] | II-III | 0 | 0 | 110 | 0 |
| Cardillo et al. [21] | 308 | VATS 55.8 ± 10.6/Open 57 ± 12.9 | II-III | 0 | 0 | 185 | 123 |
| Stefani et al. [31] | 97 | 54 [21–83] | II-III | 0 | 0 | 97 | 0 |
| Bongiolatti et al. [32] | 64 | 57.8 ± 16.4 | II-III | 0 | 0 | 30 | 34 |
| Ismail et al. [22] | 35 | 57.26 ± 18.29 | II-III | 0 | 0 | 35 | 0 |
| Semenkovitch et al. [33] | 4095 | CT 64 [11]/VATS 56 [45–69]/ Open 57 [47–69] | II | 1563 | 1313 | 0 | 1219 |
| van Middendorp et al. [26] | 186 | u-VATS 60 ± 15.2/ m-VATS 59.6 ± 14.8 | II-III | 0 | 49 | 137 | 0 |

SD, standard deviation; CT, chest tube; VATS, video-assisted thoracoscopy; m-VATS, multiportal VATS; u-VATS, uniportal VATS.
chronic organized phase (stage III) PE, characterized by multiple loculations, and fibrothorax with diffuse lung entrapment.

Our patients underwent u-VATS 10 days maximum after admission, considering also the low impact of the uniportal approach to patients general conditions with consequent low rate of conversion.

Pleural adhesions, characteristic of a stage III PE, are one of the main limitations to VATS approach in those patients, because they cause a challenging access to the thoracic cavity and the subsequent inability to perform a complete lung decortication [33].

In fact, in our experience, conversion to traditional thoracotomy was only necessary in 1 (6.25%) adult case, due to the toughness of the countless pleural adhesion.

Operating time was confirmed to be in line with the experience of other centers [23, 29, 32, 33].

Regarding postoperative course, we do not report any major complications. As Clavien–Dindo I minor complications, we report an overall complications rate of 62.07%, 40.00% in the adults group and 85.71% in the elderly group in contrast to lower rates reported in other studies [20, 23, 24, 27, 29, 31, 33, 37].

As already declared, our study cohort was older than the cohorts examined by other authors; therefore, the increased rate of minor complications could be related to elderly age and the lack of patient compliance to postoperative respiratory physiotherapy.

In relation to the chest tube removal, we report 7.56 ± 4.50 days (95% C.I. 5.85–9.27), compared to a mean stay of 6.11 ± 2.89 days (95% C.I. 5.92–6.30) in the literature [19, 22–28, 30–32].

Moreover, LOS is comparable with other referral centers experience, as shown in Table 5.

Table 5 Literature review: intra- and postoperative characteristics

| Author, year | Total population | Conversion rate (%) | Complications (%) | Operative time (min), mean ± SD or mean and (range) | LOS (days), mean ± SD or mean and (range) | Chest tube stay (days), mean ± SD or mean and (range) | 30-day mortality (%) |
|--------------|------------------|---------------------|-------------------|-----------------------------------------------|------------------------------------------|--------------------------------------------------|---------------------|
| Landreneau et al. [23] | 76 | 17.1 | NA | NA | 7.4 ± 7.2 | 3.3 ± 2.9 | 6.6 |
| Wait et al. [19] | 20 | 0 | VATS 0/CT 11.11 | NA | VATS 8.7 ± 0.9/CT 12.8 ± 1.1 | VATS 5.8 ± 1.1/CT 4.2 ± 1.8 | VATS 9.09/CT 11.11 |
| Angelillo Mackinlav et al. [24] | 64 | 9.67 | VATS 16.13/Open 15.15 | VATS 119 ± 32.5/Open 123 ± 25.8 | VATS 6.7 ± 3.0/Open 11.6 ± 9.1 | VATS 4.2 ± 1.5/Open 6.1 ± 2.3 |
| Cassina et al. [27] | 45 | 10 | NA | 10.7 [6–140] | 7.1 [4–140] |
| Roberts et al. [25] | 172 | NA | VATS 9/ Open 21 | NA | 15.3 | 10.5 | 1.8 |
| Kim et al. [28] | 70 | 1.4 | NA | 79.5 ± 15 | 5.7 ± 6 | 5 ± 2 | 0 |
| Lardinois et al. [29] | 328 | 44.38 | 9 | NA | NA | NA | VATS 3/ Open 4 |
| Salaini et al. [30] | 110 | 8.2 | 10.9 | 120 [35–220] | 7.1 [5–17] | 6 [3–25] | 0 |
| Cardillo et al. [21] | 308 | 5.94 | VATS 18.5/Open 25.2 | VATS 70 ± 7.4/Open 79.6 ± 6.8 | VATS 8.6 ± 1.8/Open 10 ± 7.8 | NA | VATS 0/ Open 3.2 |
| Stefani et al. [31] | 97 | 59 | VATS 12.5/Open 32 | VATS 146 [90–210]/Open 162 [80–255] | VATS 8.3 [3–30]/Open 8.4 [3–44] | VATS 4.4 [2–12]/Open 5 [2–40] | NA |
| Bongiolatti et al. [32] | 64 | 10 | VATS 10/Open 47 | VATS 116 ± 28/Open 135 ± 43 | VATS 6.7 ± 1.9/Open 12.2 ± 4.7 | VATS 5.6 ± 1.4/Open 10.6 ± 4.2 | 0 |
| Ismail et al. [22] | 35 | 0 | 22.8 | 128.29 ± 8.98 | 15.6 ± 8.98 | 8.91 ± 7.01 | 0 |
| Semenkovich et al. [33] | 4095 | 15 | CT 15.4/VATS 4.7/Open 6 | CT 14 [9–22]/VATS 12 [9–19]/Open 15 [10–21] | NA | CT 18.3/VATS 5.4/Open 6.8 |
| van Middep et al. [26] | 186 | u-VATS 0/m-VATS 3 | u-VATS 18/m-VATS 10 | u-VATS 65.3 ± 17.9/m-VATS 56.4 ± 23.3 | u-VATS 18.9 ± 12.8/m-VATS 20.1 ± 14.7 | u-VATS 6.4 ± 4.3/m-VATS 8.9 ± 6.2 | u-VATS 8/m-VATS 6 |

SD, standard deviation; CT, chest tube; VATS, Video-assisted thoracoscopy; m-VATS, multiportal VATS; u-VATS, uniportal VATS; LOS, length of stay
The effectiveness of u-VATS approach was investigated in the elderly also though the IADL scale. To our knowledge, this is the first report in thoracic surgery where daily living activities after emergency surgery were evaluated, with such successful outcomes.

As declared above, we found a significant longer chest tube stay and hospital stay in the elderly population. This result is due to the high prevalence of comorbidities associated with increased difficulty in the early removal of chest tubes.

Furthermore, the geographical and social limitation of Molise, already discussed in other experience [38], caused a longer hospital stay due to the lack of social supports and peripheral care, with, consequent, higher hospital related complications [39].

**Limitations**

We understand that our study shows some limitations. First, the institution of a new thoracic team into a general surgery department does not allow comparative analysis with the previous treatment. Furthermore, the learning curve on u-VATS, acquired by authors during previous experiences, allowed to directly start the u-VATS approach in PE patients.

Moreover, the limited patient sample and the lack of a comparison group (u-VATS vs. thoracotomy or fibrinolytic therapy) are the major limitations of this study. However, based on our experience, we are able to confirm the feasibility and safety of the u-VATS procedure in the treatment of PE because it permits an easy performance of a complete debridement and decortication with a very low conversion rate risk.

**Conclusions**

Despite the absence of international guidelines recognizing a precise role for u-VATS in the treatment of stage II PE, our experience recommends u-VATS as a safe alternative in patients with fibrinopurulent disease also after failure of conservative treatments. Furthermore, early u-VATS approach may allow a lower risk of progression to stage III PE and septic complications, also in the elderly.

Further comparative multicenter analyses are advocated to set the u-VATS approach as standard of care.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13017-022-00438-8.

**Acknowledgements**

Not applicable.

**Authors contributions**

CL and AR contributed to the concept and design. CL and GDM contributed to the acquisition, analysis, or interpretation of data. CL, RV, and PA drafted the manuscript. AR critically revised the manuscript for important intellectual content. RV was involved in the statistical analysis. All authors provided the administrative, technical, or material support. PA and AR contributed to the supervision. All authors read and approved the final manuscript.

**Funding**

This research received no specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

**Declarations**

**Ethical approval and consent to participate**

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of Molise (protocol number 10/21, approved date: May 12, 2021).

**Consent for publication**

All patients signed a consent for publication.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 General Surgery Unit, A. Cardarelli Hospital, Campobasso, CB, Italy. 2 Department of Medicine and Health Science, University of Molise, Campobasso, Italy. 3 General and Robotic Surgery Department, San Giovanni Battista Hospital, Foligno, Perugia, Italy.

**Received: 9 April 2022 Accepted: 29 May 2022**

**Published online: 29 August 2022**

**References**

1. Shen KR, Bribriesco A, Crabtree T, Denlinger C, Eby J, Ikem P, et al. The American association for thoracic surgery consensus guidelines for the management of empyema. J Thorac Cardiovasc Surg. 2017;153(6):e129–46.
2. Davies HE, Davies RJ, Davies CW. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:i41–53.
3. Scarcio M, Abah U, Solli P, Page A, Waller D, van Schil P, et al. EACTS expert consensus statement for surgical management of pleural empyema. Eur J Cardiothorac Surg. 2015;48(5):642–53.
4. Rocca A, Cipriani F, Belli G, Berti S, Boggi U, Bottino V, et al. The Italian Consensus on minimally invasive simultaneous resections for synchronous liver metastasis and primary colorectal cancer: A Delphi methodology. Updates Surg. 2021.
5. Ceccarelli G, Costa G, De Rosa M, Codacci Pisanelli M, Frezza B, De Prizo M, et al. Minimally invasive approach to gastric GISTs: analysis of a multicenter robotic and laparoscopic experience with literature review. Cancers (Basel). 2021;13(17).
6. Rocca A, Sciacchitani A, Cappuccio M, Avella P, Bugiantella D, De Rosa M, et al. Robotic surgery for colorectal liver metastases resection: a systematic review. Int J Med Robot. 2021;17(6):e2330.
7. Ceccarelli G, Andolfi E, Fontani A, Calise F, Rocca A, Giuliani A. Robot-assisted liver surgery in a general surgery unit with a “Referral Centre Hub&Spoke Learning Program”: Early outcomes after our first 70 consecutive patients. Minerva Chir. 2018;73(5):460–8.
8. Aprea G, Rocca A, Salzano A, Sivero L, Scarpeleggia M, Ocelli P, et al. Laparoscopic single site (LESS) and classic video-laparoscopic cholecystectomy in the elderly: a single centre experience. Int J Surg. 2016;33(Suppl 1):S1–3.
9. Yeung C, Dawson J, Gilbert S. Uniportal video-assisted thoracoscopy approach to the management of non-pulmonary diseases of the chest. J Thorac Dis. 2019;11(Suppl 16):52062–8.
10. Pastina M, Menna C, Andreetti C, Ibrahim M. The era of uniportal video-assisted thorascopic surgery. J Thorac Dis. 92017. p. 462–5.
11. Pan H, He J, Shen J, Jiang L, Liang W. A meta-analysis of video-assisted thoracoscopic decortication versus open thoracotomy decortication for patients with empyema. J Thorac Dis. 2017;9(7):2006–14.
12. Zhao R, Shi Z, Cheng S. Uniport video assisted thoracoscopic surgery (U-VATS) exhibits increased feasibility, non inferior tolerance, and equal efficiency compared with multport VATS and open thoracotomy in the elderly non-small cell lung cancer patients at early stage. Medicine (Baltimore). 2019;98(28):e16137.
13. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12(12):1500–20.
14. Owens WD, Felts JA. Spitznagel EL. Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology. 1978;49(4):239–43.
15. Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the enhanced recovery after surgery (ERAS®) Society and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2019;55(1):119–15.
16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
17. Chiariotto A, Maxwell LJ, Ostelo RW, Boers M, Tugwell P, Terwee CB. Measurement properties of visual analogue scale, numeric rating scale, and pain severity subscale of the brief pain inventory in patients with low back pain: a systematic review. J Pain. 2019;20(3):253–63.
18. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.
19. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest. 1997;111(6):1548–51.
20. Chan DT, Sihohe AD, Chan S, Tsang DS, Fang B, Lee TW, et al. Surgical treatment for empyema thoracis: is video-assisted thoracic surgery “better” than thoracotomy? Ann Thorac Surg. 2007;84(1):225–30.
21. Cardillo G, Carleo F, Carbone L, Di Martino M, Salvadori L, Petrella L, et al. Chronic postpneumonic pleural empyema: comparative merits of thoracoscopic versus open decortication. Eur J Cardiothorac Surg. 2009;36(5):914–8.
22. Ismail M, Nachira DJ, Meacci E, Ferretti GM, Swierczy M, Enghisch JP, et al. Uniportal video-assisted thoracic surgery in the treatment of pleural empyema. J Thorac Dis. 2018;10(Suppl 31):S3696–703.
23. Landreneau RJ, Keenan RJ, Hazelrigg SR, Mack MJ, Naunheim KS. Thoracoscopic empyema and hemothorax. Chest. 1996;109(1):18–24.
24. Angellino Mackinlay TA, Lyons GA, Chimondeguy DJ, Piedras MA, Angarano G, Emery J. VATS debridement versus thoracotomy in the treatment of loculated postpneumonia empyema. Ann Thorac Surg. 1996;61(6):1626–30.
25. Roberts JR. Minimally invasive surgery in the treatment of empyema: intraoperative decision making. Ann Thorac Surg. 2003;76(1):225–30.
26. van Middendorp LB, Franssen S, Gillissen S, Maessen JG, Hulséweg KWE, Wissers YLJ, et al. Uniportal video-assisted thoracoscopic surgery is a safe approach in patients with empyema requiring surgery. J Thorac Dis. 2020;12(4):1460–6.
27. Gassona PC, Hauser M, Hillelan L, Greschuchna D, Stamatis G. Video-assisted thoracoscopic surgery in the treatment of pleural empyema: stage-based management and outcome. J Thorac Cardiovasc Surg. 1999;117(2):234–8.
28. Kim BY, Oh BS, Jang WC, Min YI, Park YK, Park JC. Video-assisted thoracoscopic decortication for management of postpneumonic pleural empyema. Am J Surg. 2004;188(3):321–4.
29. Lardinois D, Gock M, Pezzetta E, Buchi C, Rousson V, Furrer M, et al. Delayed referral and gram-negative organisms increase the conversion thoracotomy rate in patients undergoing video-assisted thoracoscopic surgery for empyema. Ann Thorac Surg. 2005;79(6):1851–6.
30. Solarini L, Prucianio F, Bagioni P. Video-assisted thoracic surgery in the treatment of pleural empyema. Surg Endosc. 2007;21(2):280–4.
31. Stefani A, Aramini B, della Casa G, Libagoe G, Kaleci S, Casali C, et al. Preoperative predictors of successful surgical treatment in the management of parapneumonic empyema. Ann Thorac Surg. 2013;96(5):1812–9.
32. Bongiolarri S, Volotolini L, Borgianni S, Bonelli R, Tancredi G, Viggiano D, et al. Uniportal thoracoscopic decortication for pleural empyema and the role of ultrasonographic preoperative staging. Interact Cardiovasc Thorac Surg. 2017;24(4):560–6.
33. Semenikovich TR, Olsen MA, Pur P, Meyers F, Kozower BD. Current state of empyema management. Ann Thorac Surg. 2018;105(6):1589–96.
34. Komici K, Cappuccio M, Scacchi A, Vaschetti R, Dela Carpinelli G, Piccini V, et al. The prevalence and the impact of frailty in hepatobiliary pancreatic cancers: a systematic review and meta-analysis. J Clin Med. 2022;11(4).
35. Rocco A, Brunese MC, Cappuccio M, Scacchi A, Martucci G, Buondonno A, et al. Impact of physical activity on disability risk in elderly patients hospitalized for mild acute diverticulitis and diverticular bleeding undergone conservative management. Medicina (Kaunas). 2021;57(4).
36. Aprea G, De Rosa D, Milone M, Rocco A, Bianco T, Massia G, et al. Laparoscopic distal pancreatectomy in elderly patients: is it safe? Aging Clin Exp Res. 2017;29(5):41–5.
37. Subotic D, Lardinois D, Hojski A. Minimally invasive thoracic surgery for empyema. Breathe (Sheff). 2018;14(4):302–10.
38. Buondonno A, Avella P, Cappuccio M, Scacchi A, Vaschetti R, Di Marzo G, et al. A hub and spoke learning program in bariatric surgery in a small region of Italy. Front Surg. 2022:9.
39. Giuliani A, Avella P, Segreti AL, Izzo ML, Buondonno A, Coluzzi M, et al. Postoperative outcomes analysis after pancreatic duct occlusion: a safe option to treat the pancreatic stump after pancreaticoduodenectomy in low-volume centers. Front Surg. 2021;8:804675.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions